OptiNose, Inc. (NASDAQ:OPTN) Q3 2019 Earnings Conference Call - Final Transcript
Nov 12, 2019 • 04:30 pm ET
Peter K. Miller
And finally we are successfully completing other important corporate objectives. This includes the licensing agreement for ONZETRA XSAIL, and the ongoing conduct of our chronic sinusitis clinical program. I look forward to our future updates.
Thank you. And I would like to open up the call for Q&A.